Acrucial clinical trial of the most promising new treatment for Parkinson's disease in decades might be delayed because of a feud between a key scientist and the influential Michael J. Fox Foundation.
The prominent foundation — the richest nonprofit seeking to cure the crippling neurological disorder — initially wanted to collaborate on a study with the Georgetown University researcher. His preliminary findings last year had buoyed patients' hopes for the first Parkinson's medicine that might reverse some of their debilitating symptoms.
Read Full Article »